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Scar formationPrevious work from our group has shown that intranasal MSC-treatment decreases lesion volume and improves
motor and cognitive behavior after hypoxic–ischemic (HI) brain damage in neonatalmice. Our aimwas to deter-
mine the kinetics of MSC migration after intranasal administration, and the early effects of MSCs on neurogenic
processes and gliosis at the lesion site.
HI brain injury was induced in 9-day-old mice and MSCs were administered intranasally at 10 days post-HI. The
kinetics of MSC migration were investigated by immunoﬂuorescence and MRI analysis. BDNF and NGF gene ex-
pression was determined by qPCR analysis following MSC co-culture with HI brain extract. Nestin, Doublecortin,
NeuN, GFAP, Iba-1 and M1/M2 phenotypic expression was assessed over time.
MRI and immunohistochemistry analyses showed that MSCs reach the lesion site already within 2 h after intra-
nasal administration. At 12 h after administration the number of MSCs at the lesion site peaks and decreases sig-
niﬁcantly at 72 h. The number of DCX+ cells increased 1 to 3 days after MSC administration in the SVZ. At the
lesion, GFAP+/nestin+ and DCX+ expression increased 3 to 5 days after MSC-treatment. The number of
NeuN+ cells increasedwithin 5 days, leading to a dramatic regeneration of the somatosensory cortex and hippo-
campus at 18 days after intranasal MSC administration. Interestingly, MSCs expressed signiﬁcantly more BDNF
gene when exposed to HI brain extract in vitro. Furthermore, MSC-treatment resulted in the resolution of the
glial scar surrounding the lesion, represented by a decrease in reactive astrocytes andmicroglia and polarization
of microglia towards the M2 phenotype.
In view of the current lack of therapeutic strategies, we propose that intranasal MSC administration is a powerful
therapeutic option through its functional repair of the lesion represented by regeneration of the cortical and hip-
pocampal structure and decrease of gliosis.
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/3.0/).Introduction
Encephalopathy caused by neonatal hypoxic-ischemic (HI) brain in-
jury results in cerebral tissue loss leading to long-term neurological def-
icits e.g. mental retardation and motor impairment (De Haan et al.,
2006; Ferriero, 2004; Graham et al., 2008; van Handel et al., 2007;
Volpe, 2001).
The capacity of stem cells to treat neonatal encephalopathy is
gaining support from an increasing number of studies (Bacigaluppi
et al., 2009; Daadi et al., 2010; Donega et al., 2013a; Lee et al., 2010;
Pimentel-Coelho et al., 2010; Titomanlio et al., 2011; Yasahura et al.,gy, Department of Symptom
Center, 1515 Holecombe Blvd,
en).
. This is an open access article under2008; van Velthoven et al., 2010, 2011, 2013). These studies describe
the therapeutic potential of intracranially and intravenously delivered
neural stem cells (NSCs) or mesenchymal stem cells (MSCs) in rodent
models of neonatal HI or neonatal stroke. We have shown recently
that both intracranial and intranasal MSC-treatment at 10 d after HI in
neonatal mice signiﬁcantly decreases cerebral lesion volume and
improves long-term motor and cognitive behavior (Donega et al.,
2013a; van Velthoven et al., 2010).
In view of the therapeutic potential of non-invasive intranasal MSC
administration, we investigated the mechanism underlying MSC-
mediated repair. Firstly, we studied the kinetics of MSC migration to
the lesion site after intranasal administration. To visualize the arrival
of MSCs in the brain, we used ﬂuorescence microscopy and Magnetic
Resonance Imaging (MRI). We determined the short- and long-term ef-
fects of MSCs on regeneration of the lesion by systematic quantiﬁcation
and characterization of precursor cells (type B cells; uncommittedthe CC BY license (http://creativecommons.org/licenses/by/3.0/).
Fig. 1. Intranasal MSC treatment decreases HI lesion size. Representative images of
(A) MAP2 and (B) MBP staining from HI-Vehicle and HI-MSC animals at 18 days after
MSC administration (i.e. 28 days after HI).
54 V. Donega et al. / Experimental Neurology 261 (2014) 53–64precursors), neural progenitor cells (type A cells; neuronally-committed),
neurons, microglia and astrocytes.
Material and methods
Ethics statement
Experiments were performed according to the international guide-
lines from the EU Directive 2010/63/EU for animals experiments and
approved by the Experimental Animal Committee Utrecht (University
Utrecht, Utrecht, Netherlands).
Animals
Unilateral HI brain damage was induced in 9 day old C57BL/6 mice
(Harlan Laboratories, The Netherlands) by permanent occlusion of the
right common carotid artery under isoﬂurane anesthesia followed by
hypoxia (45 min at 10% oxygen). Sham-controls underwent anesthesia
and incision only.
MSCs were purchased from Invitrogen (GIBCO mouse C57BL/6
MSCs, Life Technologies, UK) and cultured according to the
manufacturer's instructions. Characterization of cell speciﬁc antigens
has been described previously by us (van Velthoven et al., 2011). Before
administering 1 × 106 MSCs intranasally, each nostril was treated with
3 μL of hyaluronidase (100 U, Sigma-Aldrich, St. Louis, MO) in PBS to in-
crease the permeability of the nasal mucosa. Thirty minutes later, pups
received 3 μL of MSCs or PBS (vehicle) twice in each nostril.
Histology
Coronal parafﬁn sections (8 μm) of paraformaldehyde (PFA)-ﬁxed
brains were incubated with mouse-anti-myelin basic protein (MBP)
(Sternberger Monoclonals, Lutherville, MD,) or mouse-anti-microtubule-
associated protein 2 (MAP2) (Sigma-Aldrich) followed by biotinylated
horse-anti-mouse antibody (Vector Laboratories, Burliname, CA). Binding
was visualized with Vectastain ABC kit (Vector Laboratories) and
diaminobenzamidine.
Immunohistochemistry
MSCs were labeled with PKH-26 Red Fluorescent Cell Linker Kit
(Sigma-Aldrich). Coronal frozen sections (8 μm) were incubated over-
night at 4 °C with primary antibodies; goat anti-DCX (1:300) (Santa
Cruz Biotechnology, TX, USA), rabbit anti-Iba1 (1:500) (Wako Chemicals,
Osaka, Japan), mouse anti-GFAP (1:100) (Acris antibodies, Herford,
Germany), mouse anti-NeuN (1:200) (Chemicon, Temecula, CA), mouse
anti-nestin (1:200) (BD Biosciences, Breda, The Netherlands), rat anti-
CD16/CD32 (1:300) (BD Pharmingen, Breda, The Netherlands), goat
anti-CD206 (1:300) (R&D Systems, Abingdon, UK). Primary antibody
binding was detected by incubating with corresponding secondary anti-
bodies for 1 h at room temperature (Supplementary Table 1). Nuclei
were counterstained with DAPI (Invitrogen, Paisley, UK) and mounted
with FluoroSave reagent (Calbiochem, Nottingham, UK). Fluorescent im-
ages were captured using an EMCCD camera (Leica Microsystems, Bene-
lux) and Softworx software (Applied Precision, Washington, USA) or an
AxioCam MRm (Carl Zeiss, Sliedrecht, The Netherlands) on an Axio Ob-
server Microscope with Axiovision Rel 4.6 software (Carl Zeiss).
MSC labeling for MRI
Culture ﬂasks were coated with Poly-L-Lysine (0.02 mg/mL) before
seeding MSCs. 48 h later, MSCs were incubated with 0.01 mg Fe/mL
ﬂuorescent micron-sized superpara-magnetic iron-oxide particles
(MPIO; 0.86 μm) (Bangs Laboratories Inc., IN, USA) diluted in GlutaMAX
DMEMmedium (Life Technologies). After 4 h, excessive MPIO particles
were removed bywashing 4 timeswith PBS. About 70% of the cells werelabeled with MPIO particles. Images were taken on an Axio-Observer
microscope (Carl Zeiss Microscopy, Jena, Germany) with Axiovision
rel. 4.6 software (Carl Zeiss Microscopy).MRI
MRI was performed on a 9.4 T horizontal bore preclinical MRI
system (Varian Inc., Palo Alto, CA). T2⁎-weighted gradient echo images
of cells in agarose were acquired with TR/TE = 1000/15 ms and
100 μm × 100 μm × 200 μm spatial resolution. T2⁎-weighted gradient
echo images of ex-vivo mouse brain were acquired with TR/TE = 40/
15 ms and a voxel size of 75 μm in all directions.
To verify the detectability of MPIO-labeled MSCs with MRI, cells
were homogeneously distributed in 0.4% agarose in PBS at concentra-
tions between 0 and 1000 cells/μL. T2⁎-weighted gradient echo images
were acquired with a Millipede™ coil (Varian Inc.), using the following
parameters: TR=1 s, TE=15ms, ﬂip angle= 90°, 4 averages, ﬁeld-of-
view 25.6 mm × 25.6 mm, matrix size 256 × 256 and slice thickness
0.2 mm. For the detection of MPIO-labeled cells in ex-vivo mouse
brain, mice were perfused transcardially with 4% PFA at 2 h after MSC-
treatment. T2⁎-weighted images were acquired with a 3D GE sequence,
with TR = 40 ms, TE = 15 ms, ﬂip angle = 15°, 32 averages, ﬁeld-of-
view = 22 mm × 12 mm × 10 mm and a voxel size of 75 μm in all
directions.MSCs co-culture with brain extracts
10 days after HI- or sham-operation, mice were euthanized by pen-
tobarbital overdose and decapitated, and their brains were removed.
The ipsilateral hemisphere was dissected on ice at −2.0–2 mm from
bregma and was subsequently pulverized on liquid nitrogen. Dissected
brains were dissolved in KO-DMEM medium (Life Technologies) at a
ﬁnal concentration of 150 mg/mL and centrifuged for 10 min at 3000 g
at 4 °C. Supernatants were collected as ‘brain extract’ and protein con-
centration was measured with the protein assay (Bio-Rad, Hercules,
CA). MSCs were cultured at a concentration of 40,000 cells per well in
a 24 well-plate for 24 h before replacing the medium with knock-out
medium containing 1 mg/mL brain extract. RNA was isolated from the
MSCs 72 h after culture with brain extracts.
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Total RNA was isolated with the RNAmini kit according to the
manufacturer's instructions (Invitrogen). The amount of RNAwasmea-
sured with the nanodrop 2000 (Thermo Scientiﬁc, Waltham, MA, USA).
The RNA quality was determinedwith the OD 260/280 ratio, whichwas
between 1,9 and 2,1. cDNA was synthetized with SuperScript Reverse
Transcriptase (Invitrogen). The expression of BDNF and NGF genes
was measured by quantitative reverse transcription (qRT)-PCR (Biorad
IQ5, Thermo Scientiﬁc) analysis on individual samples. We chose
these genes as they are important neurotrophic factors that have been
shown to be secreted by MSCs (Crigler et al., 2006). Data was normal-
ized for the expression of GAPDH and actin.
SDS-PAGE gel and Western blot
To assess the expression of BDNF and NGF in sham and HI brain ex-
tracts used for co-culture with MSCs, equal amounts of brain extract
were loaded on a 15% SDS-PAGE gel (Bio-Rad) and transferred to a ni-
trocellulosemembrane (Hybond C; AmershamBiosciences, Roosendaal,
Netherlands). Membranes were blocked with 5% skimmed milk for 1 h,
followed by overnight incubation with primary antibodies for rabbit
anti-BDNF 1:400 (Santa Cruz Biotechnology, Dallas, Texas) and rabbit
anti-NGF 1:1000 (Sigma-Aldrich). Expression was detected by incuba-
tion with donkey anti-rabbit-HRP 1:5000 (Amersham Biosciences)
and developed by enhanced chemiluminescence (ECL) (Advansta,
Isogen Life Science, De Meern, The Netherlands) on a ProXima Imager
(Isogen Life Science). To control for equal loading, membranes were
reprobed for β-actin followed by donkey anti-goat-HRP 1:5000 (both
Santa Cruz Biotechnology).
Data analysis
Analyses were performed in a blinded set-up. PKH-26+ signal was
determined by measuring pixel intensity with ImageJ 1.47f Software
(Wayne Rasband, National Institutes of Health, USA). Co-localization
of GFAP and nestin, CD16/CD32 and Iba-1, CD206 and Iba-1 pixels was
assessed with the co-localization macro of ImageJ 1.47f software.
GFAP and Iba-1 positive signals were also measured using the ImageJ
software. The number of DCX+ and NeuN+ cells was countedmanually.
Statistical signiﬁcance in relative mRNA expression was determined
with an unpaired two-tailed T-test. Statistical signiﬁcance betweenFig. 2.MSCs reach the lesion site within 2 h after administration. 1 × 106 PKH-26 labeled MSCs
(see arrows) at the lesion site at 2, 6, 12, 24, 48 and 72 h followingMSC administration. (B) Quan
*p b 0.05 by ANOVA and Bonferroni post-hoc test (n = 5 per group). Red = PKH-26; blue = DM1 and M2 phenotype was determined by Multiple T-test corrected
for multiple comparisons using the Holm–Sidak method. Statistical sig-
niﬁcance was analyzed using (repeated measures) one-way ANOVA
followed by Bonferroni post-tests, when not mentioned otherwise.
p b 0.05 was considered statistically signiﬁcant. Data are presented as
mean ± SEM. Outliers were identiﬁed with the Grubbs test (Q = 2%)
or the ROUT test (Q = 2%).
Results
Kinetics of MSC migration to the lesion site
We have previously shown that intranasal MSC treatment signiﬁ-
cantly decreases HI brain injury at 25 days after MSC treatment (i.e. 35
days post-HI) (Donega et al., 2013a). We assessed HI-induced loss of
MAP2 andMBP staining asmeasures for gray andwhitematter damage,
respectively. The results in Fig. 1 conﬁrm our previous data and show
that intranasal treatmentwith 0.5× 106MSCs leads to substantial repair
of both the somatosensory cortex and hippocampus, which are both se-
verely damaged after HI.
We have shown in a previous study thatMSCs administered intrana-
sally to both nostrils,migrate speciﬁcally to the ipsilateral side, but not to
the contralateral hemisphere (Donega et al., 2013a). To assess the kinet-
ics of MSC migration to the lesion site, we administered PKH-26 labeled
MSCs intranasally via both nostrils at 10 days after HI. We analyzed sec-
tions of the lesion at 2, 6, 12, 24, 48 and 72 h after administration. PKH-
26+-MSCs form clusters around the lesion site and appear to home ex-
clusively to the ipsilateral side. Our results show that PKH-26+-MSCs
reach the lesion site as early as 2 h after administration and peak at
12 h. At 72 h, the PKH-26+-MSC signal decreases bymore than 50% com-
pared to levels at 12 h after administration (Fig. 2).
MRI of MPIO-labeled MSCs
To corroborate our observation thatMSCs reach the lesion site with-
in 2 h, we performed ex-vivoMRI analysis of mouse brains using MSCs
loaded with micron-sized superpara-magnetic iron-oxide particles
(MPIO) co-labeled with the ﬂuorescent label Dragon Green. In vitro
pre-screening ofMPIO-labeledMSCs showed a strongﬂuorescent signal
indicating that MSCs had ingested MPIO particles (Fig. 3A). To verify
that contrast-induced signal intensity changes represent changes in
MPIO-MSC numbers, increasing numbers of MPIO-MSCs were assessedwere administered intranasally 10 d post-HI. (A) Representative images of PKH-26+ cells
tiﬁcation of PKH-26+ signal/mm2 at 2, 6, 12, 24, 48 and 72 h. Data representmean± SEM.
API; asterisk = lesion; dashed line = lesion border. Scale bar = 50 μm.
Fig. 3.Magnetic Resonance Imaging of MPIO labeled MSCs. 1 × 106 MPIO-labeled MSCs were administered intranasally at 10 d post-HI or sham-operation. (A) Representative phase-
contrast and ﬂuorescent image of MPIO-(Dragon Green) labeled MSCs. Dragon Green MPIOs are taken up by the MSCs. Scale bar = 10 μm. (B) T2⁎-weighted gradient echo image of cell
samples acquired at 100 × 100 × 200 μm3 spatial resolution, with TE = 15 ms. Note the increase in contrast as cell concentration increases. (C, D) Ex-vivo T2⁎-weighted images of
mouse brain (75 × 75 × 75 μm3 resolution, TE= 15ms), 2 h following intranasal administration of MPIO-labeledMSC at 10 d after HI (C) or sham-operation (D). (C) Arrows show signal
contrast fromMPIO-labeledMSCs surrounding damaged region (yellow dashed line). (E, F) Panorama of ipsilateral cortex from HI (E) or sham-operated (F)mice. Note the Dragon Green
signal in (E). scale bar = 200 μm. (E′) Iba-1 (red) staining on sections from brain shown in (E). (F′) Insert of sham-operated mice. Blue = DAPI; scale bar = 20 μm.
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correlated with MSC concentration (Fig. 3B).
MPIO-labeledMSCswere administered to both nostrils 10 days post-
HI or sham-operation and mice were sacriﬁced 2 h later. Hypo-
intensities in T2⁎-weighted images were detected speciﬁcally in regions
adjacent to the lesion site (Fig. 3C). No hypo-intensities were observed
in the brains of sham-operated mice (Fig. 3D). To validate the MRI
results, we analyzed brain sections for Dragon Green ﬂuorescence. In
the HI-injured brain we observed a strong ﬂuorescent signal clustered
in the somatosensory cortex adjacent to the lesion, in a pattern compa-
rable to theMPIO signal observedwithMRI (Fig. 3E). In agreementwith
our MRI results, no Dragon Green signal was observed in brains from
sham-operated mice (Figs. 3F, F′).
To control for the possibility that dying MPIO-labeled MSCs or free
MPIO had been taken up by microglia in vivo, we also analyzed
colocalization of Iba-1 and Dragon Green. The results show that Iba-
1+ cells surround the Dragon Green ﬂuorescent signal without overlap-
ping (Fig. 3E′).Neurotrophic factor expression by MSCs
To determinewhether the HI brain environment stimulates MSCs to
express the neurotrophic factors BDNF and NGF, we co-cultured MSCs
with HI or sham-operated brain extracts from 10 days post-insult. Our
results show that BDNF mRNA expression signiﬁcantly increases after
co-culture with HI brain extract, but not with sham-operated brain
extract (Fig. 4C). NGF gene expression increased after co-culture with
both HI and sham brain extracts (Fig. 4C).Characterization of the early regenerative niche at the lesion
To characterize the cellular environment surrounding the MSCs at
the lesion site, we stained ipsilateral brain sections at 1 day after MSC-
treatment for NeuN, GFAP and Iba-1. PKH-26+-MSCs were primarily
surrounded by Iba-1+ cells (Fig. 4A). NeuN+ cells were found scattered
around the MSCs. GFAP+ cells formed a boundary border around the
Fig. 4.Characterization of the cellular niche at the lesion and neurotrophic factor expression byMSCs. (A) Brain sections from24h afterMSC-treatmentwere stained for NeuN (green), Iba-
1 (green) and GFAP (green) expression. (n = 3 per group); red = PKH-26; blue = DAPI; scale bar = 50 μm. (B) Overlap between Iba-1+ cells and PKH-26+ signal at 2 h after MSC
administration. Green = Iba-1; red = PKH-26; scale bar = 20 μm. (C) Relative mRNA expression of BDNF and NGF by MSCs at 72 h after co-culture without brain extract or with either
HI or sham-operated brain extract (n = 2). Data represent mean ± SEM. * p b 0.05; **p b 0.01 by unpaired two-tailed T-test.
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NeuN+, GFAP+ or Iba-1+ cells at 1 day. To determine whether Iba-1+
cells overlapped with PKH-26+-MSCs at an earlier time-point, we
stained brain sections at 2 h following MSC-treatment for Iba-1. At
this early time-point, we estimate that around 80% of the Iba-1+ cells
overlapped with the PKH-26+-MSC-derived signal suggesting that
Iba-1+ cells may phagocytose dying MSCs (Fig. 4B).
MSCs increase the number of DCX+ cells in the SVZ
First, we investigated whether MSCs affect neurogenesis in the SVZ.
To this end, we assessed the number of neuronally-committed type A
progenitor cells, i.e. neuroblasts, which have the phenotype of young
migrating neurons. Coronal sections from the SVZ were stained for
doublecortin (DCX) at 1, 3 and 5 days after MSC- or vehicle-treatment.
MSC administration signiﬁcantly increased the number of DCX+
cells in the SVZ at 1 and 3 days (Figs. 5A–C). At 5 days after MSC-
treatment, the number of DCX+ cells had returned to the level observed
in sham-operated mice (Fig. 5D). DCX+ cell numbers increased in the
contralateral SVZ at 1 day. HI alone did not lead to a signiﬁcant increase
in the number of DCX+ cells at any of the time-points measured (Fig. 5).Early effect of MSCs on neural progenitor cells at the lesion
Next, we determined the number of type B precursor cells (i.e. un-
committed precursors) at the lesion site, by quantifying the expression
of GFAP+/nestin+ pixels in 10 ﬁelds, at 1, 3 and 5 days after MSC or ve-
hicle administration (Fig. 6A). Our results show that the number of
GFAP+/nestin+ pixels at 1 day after MSC-treatment is almost two
times higher than in HI-Vehicle or sham-operated animals (Figs. 6B,
C). At 5 days the amount of GFAP+/nestin+ pixels had returned to
sham level. HI only led to a small signiﬁcant increase in GFAP+/nestin+
expression on day3. In sham-operatedmice, GFAP+/nestin+ expression
remained stable over time. In HI-Vehicle and HI-MSC animals, GFAP+/
nestin+ cells were located at the lesion border. These data show that
MSC enhance the number of type B precursor cells at the lesion, which
suggests the formation of a neurogenic niche.
Next, we quantiﬁed the number of DCX+ cells at the lesion. At both 1
and 3 days after MSC-treatment there was a signiﬁcant increase in
DCX+ cells in the corpus callosum, and in the ipsilateral cortical and tha-
lamic regions adjacent to the lesion (Figs. 7A, C). At 5 days, the number
of DCX+ cells in the ipsilateral hemisphere had returned to sham level
(Figs. 7A, D). However, at this time-point the number of DCX+ cells in
Fig. 5.MSCs increase the expression ofDCX in the SVZ. DCX expression in the SVZ at 1, 3 and 5 d afterMSC or vehicle administration and in sham-operated brain. (A) Representative images
of sham, HI-Vehicle or HI-MSC at 1, 3 and 5 d after treatment. (B–D) Quantiﬁcation of DCX+ cells in the contra- and ipsilateral SVZs at 1 d (B), 3 d (C) and 5 d (D). Data represent mean±
SEM. *p b 0.05; **p b 0.01; ***p b 0.001; n.s. = not signiﬁcant by ANOVA and Bonferroni post-hoc test (n = 6 per group). Red = DCX; blue = DAPI; scale bar = 32 μm.
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than in the contralateral area (Fig. 7D). In HI-Vehicle mice, DCX expres-
sion at the lesion or contralateral sidewas not changed at 1 to 5 days (i.e.
11–15 days post-HI) (Fig. 7). DCX expression remained constant in
sham-operated mice. These results demonstrate that MSCs also en-
hance the number of neuronally-committed progenitor cells at the
lesion.
MSCs regenerate the lesioned brain
Next,we investigatedwhetherMSC-treatment leads to increased re-
population of lost brain structures. We determined the number of
NeuN+ cells in the damaged somatosensory cortex and hippocampus
at 1, 5 and 18 days after MSC- or vehicle-treatment. Our results show
a signiﬁcant loss of tissue, encompassing the hippocampus and somato-
sensory cortex, which can be clearly discerned as a cavity at 11 days
after HI (i.e. 1 day after MSC- or vehicle-treatment) (Fig. 8A). In HI-
Vehicle mice this cavity was still discernible at 18 days (Fig. 8A). The le-
sion in the somatosensory region was repopulated by NeuN+ cells at
5 days followingMSC-treatment, and the number of neurons had signif-
icantly increased compared to HI-Vehicle mice, and reached sham-level(Figs. 8B, C). At 18days afterMSC-treatment, NeuNexpression in the so-
matosensory cortex was still increased. At 5 days following MSC-
treatment, an area with hippocampal morphology started to emerge
(Fig. 8D). At this time point, NeuN+ cells repopulated the dentate
gyrus and we also observed a partial recovery of the CA1, CA2 and
CA3 regions. At 18 days, the dentate gyrus, CA1, CA2 and CA3 regions
had further regenerated and the hippocampal structure was clearly dis-
cernible (Fig. 8D).
Effect of MSCs on astrocyte and microglia activation
To assess whetherMSC-treatment has an effect on the number of as-
trocytes and microglia, we quantiﬁed expression of GFAP+ and Iba-1+
cells at 1, 5 and 18 days after MSC- or vehicle-treatment. Figs. 9A and
B show that the number of microglia and astrocytes are substantially
upregulated at the lesion at all time-points. Following HI, Iba-1+ cells
show morphological characteristics that correlate with an activated
state (amoeboid phenotype) (Fig. 9A). GFAP+ cells change their star
shape morphology to a more rounded, multipolar morphology. A
dense network of reactive astrocytes demarcates the entire lesion
(Fig. 9B). At 1 day after MSC-treatment, no signiﬁcant difference in
Fig. 6. Expression of neural precursor cells increases following MSC-treatment. GFAP and nestin expression at the lesion site at 1, 3 and 5 d after MSC or vehicle treatment and in sham-
operated brain. (A) Schematic illustration of regions that were quantiﬁed. (B) Quantiﬁcation of GFAP+/nestin+ pixels at 1, 3 and 5 d. (C) Representative images of sham, HI-Vehicle or HI-
MSC at 1 d after treatment. Data represent mean± SEM. *p b 0.05; ***p b 0.001; n.s. = not signiﬁcant by ANOVA and Bonferroni post-hoc test (n= 6 per group). Green= Nestin; red=
GFAP; blue = DAPI; scale bar = 20 μm.
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MSC-treated mice (Figs. 9A, B). However, at 18 days following MSC-
treatment, GFAP and Iba-1 expression levels are substantially decreased
compared to levels in vehicle-treated HI mice and have returned to
sham level (Figs. 9A, B).
Polarization of microglial cells following MSC-treatment
As microglia can have distinct phenotypes, e.g. pro-inﬂammatory
(M1) or regenerative/anti-inﬂammatory (M2a/b), we assessedwhether
MSC-treatment affects microglia polarization. We double-stained coro-
nal sections for CD16/32 (M1) or CD206 (M2) and Iba-1. Our data show
that HI-Vehicle mice have a higher expression of both M1 and M2 mi-
croglia than sham-operated mice, but no signiﬁcant polarization to-
wards the M1 or the M2 phenotype (Figs. 9C, D). MSC-treatment
induced polarization towards the M2 phenotype.
Discussion
In view of the pre-clinical efﬁcacy of MSC-treatment and the lack of
effective therapies for infants with neonatal brain damage, intranasal
MSC administration might become a powerful therapeutic strategy in
the future. In previous studies we described the potent effect that
MSCs have in decreasing lesion size and improvingmotor and cognitive
behavior following HI injury (Donega et al., 2013a; van Velthoven et al.,
2010, 2011, 2013). Yet, how MSCs mediate this effect is unclear. Here,
we describe the effect of intranasally administered MSCs on the cellular
composition of the ‘regenerative niche’ in the SVZ and lesion.Moreover,
we followed repair of the lesion by quantifying the number of GFAP+/
nestin+, DCX+ and NeuN+ cells, astrocytes and microglia until
18 days after MSC-treatment (i.e. 28 days post-HI). Followingapplication of MSCs, cells migrate from the ipsi- and contralateral
nasal cavities to the unilateral lesion within 2 h after administration.
The number of MSCs decreases sharply at 72 h, which is in accordance
with previous ﬁndings (van Velthoven et al., 2011). This indicates that
MSCs induce a cascade of events leading to tissue repair. MSCs not
only increase the number of GFAP+/nestin+ and DCX+ cells at the
lesion within 1 day after intranasal administration, but also induce
maturation of neuroblasts following HI brain injury (Fig. 10). More-
over, MSCs induce microglial polarization towards a M2 phenotype
and decrease the number of activated astroglial cells at 18 days
after treatment. Our key ﬁnding is that intranasal MSC-treatment
leads to a remarkably fast regeneration of the lesion, as repopulation
of the somatosensory and hippocampal regions starts within 5 days
after administration.
The MSC signal detected with MRI and Dragon Green ﬂuorescence
surrounding the lesion at 2 h after administration (Fig. 3) closely resem-
bles the PKH-26+MSC signal, which forms clusters alongside the lesion
(Fig. 2). We checked for the possibility that MPIOs are phagocytosed by
microglia, thereby leading to false positive results. However, Iba-1 stain-
ing showed no overlapwith theMPIO-labeledMSCs, further supporting
that the MRI signal and the Dragon Green ﬂuorescence correspond to
the presence of MSCs at the lesion. Yet, at 2 h after MSC administration,
around 80% of the PKH26+ signal overlapped with Iba-1+ microglia
(Fig. 4B). In contrast, at 1 day there was no overlap between the Iba-
1+ signal and the PKH26+ signal (Fig. 4A). To explain the apparent dis-
crepancy between results we postulate that the ﬁrst MSCs reaching the
lesion at 2 h will be phagocytosed by activated microglia, whichmay in
turn affect the local brain environment that will shift towards an envi-
ronment more receptive for MSCs. Hence, at 12 h, when there is a
peak in the number of MSCs in the lesion, the environment is more re-
ceptive to theMSCs, which are no longer phagocytosed. The fact thatwe
Fig. 7.DCX expression is increased at the lesion site followingMSC-treatment. DCX expression at the lesion at 1, 3 and 5 d afterMSC or vehicle administration and in sham-operated brains.
(A) Representative images of sham, HI-Vehicle or HI-MSC at 1, 3 and 5 d after treatment. (B–D)Quantiﬁcation of DCX+ cells adjacent to the lesion and at the undamaged contralateral side
at 1 d (B), 3 d (C) and 5 d (D). Data represent mean± SEM. *p b 0.05; **p b 0.01 by ANOVA and Bonferroni post-hoc test (n= 6 per group). Red=DCX; blue = DAPI; asterisk = lesion;
dashed line = lesion border. scale bar = 32 μm.
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signal at 2 h after MSC administration might be due to the relatively
strong Dragon Green staining (Fig. 3E′).
Our ﬁnding that MSCs reach the damaged area within 2 h makes it
unlikely thatMSCsmigrate to the lesion through the brain parenchyma.
Neural precursor cells have been shown to migrate 94 μm± 20 μm per
hour along the rostral migratory stream (RMS) (Murase and Horwitz,
2002). Hence, if one would assume that MSCs migrate at a similar rate
it would take several days to reach the damaged region. Therefore, it
seems more plausible that MSCs migrate from the intranasal cavity to-
wards the lesion through the meningeal circulation or along blood ves-
sels in the lamina propria or via the cerebral spinal ﬂuid.
In order to study whether MSCs increase the number of neuronally-
committed cells in the neurogenic niche in the SVZ, we determined the
presence of DCX+ cells in the SVZ. We show that MSCs increase the
number of neuroblasts in the ipsilateral SVZ at 1 and 3 days after treat-
ment (Fig. 5). As we did not ﬁnd MSCs in the SVZ region at any time-
point, we postulate that MSCs at the lesion induce neurotrophic factor
production in the SVZ, possibly through paracrine signaling by MSCs,
which in turn promotes differentiation of type B precursor cells towards
neuroblasts in the SVZ. The fact that most of the increase in DCX+ cellsin the SVZ was detected in the ipsilateral side indicates that MSC
presence at the lesion leads to increased precursor cells in the SVZ.
These results raise the interesting possibility that neuroblasts in the
SVZmaymigrate towards the lesion to repopulate the damaged cortical
areas (Inta et al., 2008; Kempermann et al., 2004; Zhao et al., 2008).
Anderova et al. (2011) described that HI increases the number of
GFAP+/nestin+ NSCs in the hippocampus in adult rats. Neonatal HI
has also been demonstrated to increase the number of neuroblasts in
the lesion 1–3 weeks post-insult (Fagel et al., 2006; Felling et al.,
2006; Kadam et al., 2008). We detected a small increase of GFAP+/
nestin+ expression at the lesion at 3 days (i.e. 13 days post-HI) after
vehicle-treatment. We did not observe any change in DCX expression
after vehicle-treatment. Therefore, we conclude from our data that
neurogenesis is impaired following neonatal HI, which is in accordance
with current literature (Donega et al., 2013b). In contrast, 1 day after
MSC-treatment, the number of GFAP+/nestin+ cells surrounding the le-
sion had increased almost two times in comparison to HI-Vehicle mice
(Fig. 6). At 5 days after MSC administration the number of precursor
cells had returned to sham level. Moreover, we found a substantial in-
crease in DCX+ cells at 1 and 3 days after MSC, which declined to
sham level at 5 days (Fig. 7).
Fig. 8. Regeneration followingMSC administration. NeuN expression at 1, 5 and 18 d following vehicle orMSC administration. (A) Overview of themacroscopic lesion site at 1, 5 and 18 d
after vehicle orMSC-treatment. Note cortical Layer 4 (arrow) at 5 and 18 d afterMSC-treatment. Red square= insert shown in (C); green square= insert shown in (D). (B) Quantiﬁcation
of NeuN+ cells in 4 random ﬁelds in the ipsilateral somatosensory cortex. (C) Representative images of NeuN expression in the somatosensory cortex of HI-Vehicle and HI-MSC.
(D) Representative images of NeuN expression in the hippocampal structure at 1, 5 and 18 d following MSC or vehicle-treatment. Data represent mean ± SEM. *p b 0.05; **p b 0.01;
***p b 0.001 by ANOVA and Bonferroni post-hoc test (n = 6 per group). green = NeuN; blue = DAPI; Asterisk = lesion site; Dashed line = boundary lesion. scale bar = 50 μm in C, D.
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Fig. 9.MSCs revert astrogliosis at the damaged region. Iba-1 andGFAP expression at the lesion at 1, 5 and 18 d afterMSC orVehicle administration. (A) Upper: Quantiﬁcation of Iba-1+ at 1,
5 and 18 d and a schematic view of the regions that were quantiﬁed in (A), (B) and (C). Lower: Representative images of Iba-1+ cells in sham, HI-Vehicle and HI-MSC at 18 d. (B) Upper:
Quantiﬁcation of GFAP+ pixels at 1, 5 and 18 d. Lower: Representative images of GFAP+ cells in sham, HI-Vehicle and HI-MSC at 18 d. (C) Quantiﬁcation of CD16/32+/Iba-1+ pixels and
CD206+/Iba-1+ pixels at 5 d. (D) Representative images of CD16/32+/Iba-1+ cells and CD206+/Iba-1+ cells at 5 d after MSC-treatment. Data represent mean ± SEM. (A, B). *p b 0.05;
**p b 0.01; ***p b 0.001; #=not signiﬁcant for sham5d vsHI-MSC5d and sham18d vsHI-MSC 18d byANOVAandBonferroni post-hoc test. (C) *p b 0.05 bymultiple T-test correctedwith
the Holm–Sidak method (n = 6 per group). Red = Iba-1 (A, D); green = GFAP (B), CD206, CD16/CD32 (D); blue = DAPI; scale bar = 20 μm.
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short-lasting as at 5 days after MSC administration it had returned to
sham level suggesting that the DCX+ cells had either differentiated to
a more mature phenotype or died. As GFAP+/nestin+ cells ﬁrst become
nestin+ before differentiating towards DCX+ cells, we also investigated
whether the GFAP+/nestin+ cells had differentiated towards the
nestin+ intermediate phenotype at 5 days. We found that at 5 days,
nestin+ cells are still signiﬁcantly increased in the lesion in comparison
to sham, which suggests that the GFAP+/nestin+ cells have become
type 2 precursor cells at 5 days (data not shown). These data suggest
that the differentiation of nestin+ cells into adult neurons and astro-
cytes may continue after 5 days following MSC treatment.
Next, we investigated whether the DCX+ cells had further differen-
tiated into more mature neurons, by assessing the number of NeuN+
cells after MSC- and vehicle-treatment. Our results show extensive tis-
sue loss encompassing the somatosensory cortex and hippocampus1 day (i.e. 11 days post-HI) following vehicle- or MSC-treatment.
Furthermore, we observed that in the vehicle-treated mice the lesion
size did not aggravate any further after 11 days post-HI. However, at
5 days after MSC-treatment the number of NeuN+ cells increases signif-
icantly reaching sham level. TheseNeuN+ cellswill repopulate thedam-
aged somatosensory cortex resulting in cortical lamination as Layer 4
can be clearly distinguished (Figs. 8A–C). The hippocampal region also
starts to regenerate at 5 days after MSC-treatment. The dentate gyrus
is well deﬁned and the CA1, CA2 and CA3 regions are beginning to re-
populate. The CA1, CA2 and CA3 regions develop further at 18 days.
The fact that at 10 days post-HI, there is signiﬁcant tissue loss and the
lesion does not augment, does not support a neuroprotective role for
MSCs in our model. Instead, the results strongly support that MSC in-
duced lesion repair is due to increased neuroregeneration.
MSCs are known to have a strong immunomodulatory capacity and
to decrease inﬂammatory responses following injury (Tse et al., 2003;
Fig. 10. Schematic overview of location and changes in number of MSCs, precursor cells and glial cells. (A) Schematic ﬁgure showing location of MSCs, GFAP+/nestin+, DCX+, GFAP+ and
Iba-1+ cells at the lesion at 1 d after administration. (B) Diagram depicting changes in MSC, GFAP/nestin, DCX, NeuN, GFAP and Iba-1 expression over time.
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been shown to be a (functionally) heterogeneous cell population that
can be either detrimental to neurogenesis or supportive of neuronal
function (Garcia et al, 2004, Rusnakova et al., 2013; Salem and
Thiemermann, 2010; Sofroniew, 2013). Whether astrocytes will lead
to astrogliosis and impair regeneration or promote neurogenesis and re-
pair, depends on a plethora of signals including pro-inﬂammatory (e.g.
IFN-γ and IL-1) and damage signals (e.g. DAMPs and PAMPs)
(Sofroniew, 2013). At 1 day after vehicle- or MSC-treatment we ob-
served a signiﬁcant amount of GFAP+ cells surrounding the lesion. In-
terestingly, 18 days after MSC-treatment the amount of GFAP+
expressing cells had decreased back to sham level (Fig. 9), which sug-
gests that MSCs may also decrease gliosis, since in HI-Vehicle animals
there is still a dense network of reactive astrocytes at the lesion border.
Microglia, like astrocytes, can have either a pro-inﬂammatory effect
(M1) or promote tissue repair and anti-inﬂammation (M2) (Chor et al.,
2013; Czeh et al., 2011; Neumann et al., 2006; Wake et al., 2013). We
show that MSCs stimulate microglia polarization towards a M2 pheno-
type (Fig. 9). This may be mediated by the immunosuppressive effects
of MSCs. In this respect, it is of interest that we have shown increased
IL-10 mRNA expression after MSC transplantation (van Velthoven et al.,
2011). MSC-treatment decreases the number of microglia at 28 days
after HI, the time-point when repair of the lesion by NeuN+ cells was
observed. These ﬁndings suggest that lesion repair is associated with
an anti-inﬂammatory environment and that the immunosuppressive
capacity of MSCs play an important role in mediating regeneration fol-
lowing HI injury (Kokaia et al., 2012).
In conclusion, the results in this study demonstrate that intranasal
MSCs decrease lesion volume by promoting formation of a ‘neurogenic
niche’ leading to a dramatic reconstruction of the hippocampus and so-
matosensory cortex (Fig. 8). This is crucial as the regenerative signal in-
duced by HI is largely insufﬁcient (Donega et al., 2013b). Our present
study demonstrates that MSCs boost the endogenous regenerative ca-
pacity by promoting neurogenesis and neuronal survival. Importantly,
we show evidence that MSCs are directly involved in inducing and
supporting a shift to a neurogenesis supportive environment, as we
found that MSCs express more BDNF following contact with a HI envi-
ronment. Co-culture of MSCs with brain extract from sham-operated
mice doubles the mRNA expression of NGF. In contrast to BDNF, co-
culture with HI brain extract does not further increase the production
of NGF. This may suggest that factors present in the brain of sham ani-
mals stimulate MSCs to maintain production of NGF. Following injury,
endogenous stimuli in the brain will increase the production of BDNF
by MSCs to promote neurogenesis. Therefore, this suggests that the HI
brain environment stimulates MSCs to secrete speciﬁc neurotrophicfactors (see also Supplemental Fig. 1). The neurotrophic factor BDNF
plays an important role in proliferation, migration, differentiation and
survival of neuronal cells (Yuan, 2008). Moreover, we have previously
shown that intracranially-administered MSCs upregulate gene expres-
sion of several neurotrophic factors (van Velthoven et al., 2011). Both
the SVZ and lesion sitemay be sources of progenitor cells. MSCsmay in-
duce migration of DCX+ cells from the SVZ to the lesion and also stim-
ulate a subset of reactive astrocytes in the lesion to develop stem cell
potential. MSCs also revert scar formation, which is known to impair
neurogenesis. These ﬁndings are of clinical importance as they further
delineate the power ofMSCs as a future therapeutic strategy for neonatal
HI brain damage.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.expneurol.2014.06.009.
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